Advertisement

Topics

Search Results for "Xarelto Vs Pradaxa"

11:20 EDT 27th July 2016 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

With First Trials On Horizon, Value Of Growing Philly Xarelto Claims Uncertain

It might be more than a year from now, but litigation centered on the blood thinner Xarelto could eventually come to trial in Philadelphia courtrooms – and one attorney says the thousands of cases f...

Xarelto Lawsuits Now Exceed 3,000 in Number

NEW ORLEANS, Feb. 11, 2016 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Settlement Funding Company, reported today that the number of filed lawsuits against Bayer and Johnson & Johnson's subsidiary,...

Relief For Pradaxa: Praxbind Gets HTA Green Light

Pradaxa has so far not fared as well as the competition in global markets because it has a twice-daily dosing schedule and has higher rates of gastrointestinal intolerability, bleeding, and myocardial...

Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care

• New data show Pradaxa® reduced stroke risk and major bleeding compared to warfarin in patients with non-valvular atrial fibrillation1 • Pradaxa® was associated with 28% and 26% reductions in s...

EMA offers reassurance after Xarelto trial fault

Stroke-prevention drug Xarelto (rivaroxaban) can still be used safely even though a faulty device was…

News and press releases: EMA concludes defective device in ROCKET study does not impact Xarelto’s safety

Study is the main trial supporting use of Xarelto in atrial fibrillation

Bayer's Xarelto 'Safe' Despite ROCKET Device Defect

The conclusions provide reassurance for the top-selling product ahead of Bayer's full year results presentation on Feb. 25. Xarelto posted sales of €571m in 3Q 2015, missing expectations but stil...

The potential of reversal agents for target-specific oral anticoagulants

After more than 60 years of having only warfarin as an option for oral anticoagulation, several target-specific oral anticoagulants have entered the market.These agents include a direct thrombin inhib...

Matching PubMed Articles

Praxbind Available as Antidote to Bleeding from Pradaxa.

Pharmaceutical Approval Update.

Idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa); aripiprazole lauroxil (Aristada) for the treatment of schizophrenia; and insulin degludec injection (Tresiba) for ...

Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.

Rivaroxaban (Xarelto) does not require routine coagulation monitoring; however, in certain clinical situations (overdose, drug accumulation, urgent surgery) measurement of its plasma concentration is ...

Bilateral Spontaneous Hyphema, Vitreous Hemorrhage, and Choroidal Detachment With Concurrent Dabigatran Etexilate Therapy.

A 79-year-old woman was referred for rapid onset of painless bilateral vision loss. Anterior segment exams revealed bilateral spontaneous hyphema and fibrin accumulation. Observation of the posterior ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement